Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
Status:
Suspended
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This phase II/III trial tests whether it is possible to decrease the chance of high-grade
B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual
combination of drugs used for treatment. Venetoclax may stop the growth of cancer cells by
blocking a protein called Bcl-2. Drugs used in usual chemotherapy, such as rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide, work in different ways
to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving venetoclax together with usual
chemotherapy may work better than usual chemotherapy alone in treating patients with
high-grade B-cell lymphomas, and may increase the chance of cancer going into remission and
not returning.